A practical reference on HGF/c-Met: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-01 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
== Research and career == Franz became an assistant professor at Duke University in 2003. She is an Associate member of the Duke Cancer Institute. In 2005, Franz was awarded an National Science Foundation CAREER Award. She was made a Sloan Research Fellow in 2008 and promoted to professor in 2015. Franz has investigated the use of cellular metals in antimicrobial resistance. For example, by disrupting the amount of iron in a cell it is possible to withhold an essential pathogen, limiting the growth of microbes. On the other hand, copper can be used to control the growth of microbes, and immune cells appear to move copper to kill pathogens. At the same time, pathogens try to use copper to enhance their resistance and likelihood of survival. Franz attempts to use copper in the same way as biological systems to target antimicrobial agents. She has looked at iron and copper as ionophores; which are important in the virulence of Cryptococcus neoformans. Franz also works on anti-cancer prochelators; molecules that do not have much affinity for metal ions, but can be triggered until they undergo a chemical conversion. Cancer cells have different metallomes than normal cells. For example, prostate cancer results in the overexpression of copper trafficking proteins, causing a high level of copper. She looks to target these copper ions by creating prochelators that become activated in the microenvironment of cancer.
== Further reading == A, Graziano; F, Bianco; A, D'Amico; I, Moroni; S, Messina; C, Bruno; E, Pegoraro; M, Mora; G, Astrea (2015-03-01). "Prevalence of congenital muscular dystrophy in Italy: a population study". Neurology. 84 (9): 904–911. doi:10.1212/WNL.0000000000001303. ISSN 0028-3878. PMC 4351663. PMID 25653289. Paco, Sonia; Casserras, Teresa; Rodríguez, Maria Angels; Jou, Cristina; Puigdelloses, Montserrat; Ortez, Carlos I.; Diaz-Manera, Jordi; Gallardo, Eduardo; Colomer, Jaume (2015-12-15). "Transcriptome Analysis of Ullrich Congenital Muscular Dystrophy Fibroblasts Reveals a Disease Extracellular Matrix Signature and Key Molecular Regulators". PLOS ONE. 10 (12) e0145107. Bibcode:2015PLoSO..1045107P. doi:10.1371/journal.pone.0145107. ISSN 1932-6203. PMC 4686057. PMID 26670220. Falsaperla, Raffaele; Praticò, Andrea D.; Ruggieri, Martino; Parano, Enrico; Rizzo, Renata; Corsello, Giovanni; Vitaliti, Giovanna; Pavone, Piero (31 August 2016). "Congenital muscular dystrophy: from muscle to brain". Italian Journal of Pediatrics. 42 (1): 78. doi:10.1186/s13052-016-0289-9. ISSN 1824-7288. PMC 5006267. PMID 27576556. "Summary of Evidence-based Guideline for PATIENTS and their FAMILIES CONGENITAL MUSCULAR DYSTROPHY". aaan.com. The American Academy of Neurology (AAN). Retrieved 5 December 2017.
The Financial Transactions and Reports Analysis Center of Afghanistan (FinTRACA) was established as a Financial Intelligence Unit under the Anti Money Laundering and Proceeds of Crime Law passed by decree late in 2004. The main purpose of this law is to protect the integrity of the Afghan financial system and to gain compliance with international treaties and conventions. The Financial Intelligence Unit is a semi-independent body that is administratively housed within the Central Bank of Afghanistan (Da Afghanistan Bank). The main objective of FinTRACA is to deny the use of the Afghan financial system to those who obtained funds as the result of illegal activity, and to those who would use it to support terrorist activities. To meet its objectives, the FinTRACA collects and analyzes information from a variety of sources. These sources include entities with legal obligations to submit reports to the FinTRACA when a suspicious activity is detected, as well as reports of cash transactions above a threshold amount specified by regulation. Also, FinTRACA has access to all related Afghan government information and databases. When the analysis of this information supports the supposition of illegal use of the financial system, the FinTRACA works closely with law enforcement to investigate and prosecute the illegal activity. FinTRACA also cooperates internationally in support of its own analyses and investigations and to support the analyses and investigations of foreign counterparts, to the extent allowed by law.
=== Metabolism === Quercetin is rapidly metabolized (via glucuronidation) after the ingestion of quercetin foods or supplements. Five metabolites (quercetin glucuronides) have been found in human plasma after quercetin ingestion. Taken together, the quercetin glucuronides have a half-life around 11–12 hours. In rats, quercetin did not undergo any significant phase I metabolism. In contrast, quercetin did undergo extensive phase II (conjugation) to produce metabolites that are more polar than the parent substance, hence are more rapidly excreted from the body. In vitro, the meta-hydroxyl group of catechol is methylated by catechol-O-methyltransferase. Four of the five hydroxyl groups of quercetin are glucuronidated by UDP-glucuronosyltransferase. The exception is the 5-hydroxyl group of the flavonoid ring, which generally does not undergo glucuronidation. The major metabolites of orally absorbed quercetin are quercetin-3-glucuronide, 3'-methylquercetin-3-glucuronide, and quercetin-3'-sulfate. A methyl metabolite of quercetin has been shown in vitro to be more effective than quercetin at inhibiting lipopolysaccharide-activated macrophages. Compared to other flavonoids, quercetin is one of the most effective inducers of the phase II detoxification enzymes. In vitro studies show that quercetin is a strong inhibitor of the cytochrome P450 enzymes CYP3A4 and CYP2C19 and a moderate inhibitor of CYP2D6. Drugs that are metabolized by these pathways may have increased effect.
Sources: en.wikipedia.org
organised the Poor People's Campaign to address issues of economic and social justice while personally showing sympathy with democratic socialism. The classic Port Huron Statement of the Students for a Democratic Society combined a stringent critique of the Stalinist model with calls for a democratic socialist reconstruction of society. In reaction to the Tet Offensive, protests also sparked a broad movement in opposition to the Vietnam War all over the United States and even into London, Paris, Berlin and Rome. Mass socialist or communist movements grew not only in the United States, but also in most European countries. The most spectacular manifestation of this was the May 1968 protests in France in which students linked up with strikes of up to ten million workers and the movement seemed capable of overthrowing the government, albeit for only a few days. In many other capitalist countries, struggles against dictatorships, state repression and colonisation were also marked by protests in 1968 such as the beginning of the Troubles in Northern Ireland, the Tlatelolco massacre in Mexico City and the escalation of guerrilla warfare against the military dictatorship in Brazil. Countries governed by Marxist–Leninist parties had protests against bureaucratic and military elites. In Eastern Europe, there were widespread protests that escalated particularly in the Prague Spring in Czechoslovakia. In response, the Soviet Union occupied Czechoslovakia, but the occupation was denounced by the Italian and French communist parties as well as the Communist Party of Finland.
Maggot therapy improves healing in chronic ulcers. In diabetic foot ulcers there is tentative evidence of benefit. A Cochrane review of methods for the debridement of venous leg ulcers found maggot therapy to be broadly as effective as most other methods, but the study also noted that the quality of data was poor. In 2003, the United States Food and Drug Administration (FDA) cleared maggots from the common green bottle fly for use as a "medical device" in the US for the purpose of treatment of:
=== Function in pregnancy === Progesterone plays a crucial role in pregnancy by supporting fetal development and maintaining the pregnancy. It is involved in the menstrual cycle, implantation, and is required for pregnancy maintenance. During implantation, it plays a role in its preservation through modulating the maternal immune response and suppressing the inflammatory response. By decreasing the maternal immune response, progesterone can allow the pregnancy to be accepted. Progesterone prepares the endometrium for implantation, as the level of progesterone increases, the capillaries grow. These capillaries spread throughout the granulosa layer of cells which promotes vascularization and blood flow in the endometrium, ensuring an adequate blood supply to the developing placenta and fetus. On the other hand, when there is no pregnancy occurred, the level of progesterone will decrease, which leads to menstruation. This means that bleeding from women's menstruation is bleeding after progesterone withdrawal.
==== Predictors of greater weight loss ==== Patient selection is an important consideration for any weight loss therapy. The present published literature shows either no influence or conflicting results for patient age, sex, starting weight/BMI on weight loss from ESG. Long-term after care programs have demonstrated benefit for sustained weight loss after ESG, with one study showing that patients who continued after care visits following ESG had 20.5% total body weight loss compared to 16.9% total body weight loss in those who dropped out of long-term follow up programs.
=== Division of Animal Nutrition === In March 1927, due to the concerted efforts of Professor David Rivett, and following an agreement with the University of Adelaide that Robertson could continue his relationship with the university, Robertson became the head of the CSIR's first-ever division, the Division of Animal Nutrition. A red brick two-storey building, funded by the Commonwealth Government, and dedicated to animal nutrition research, was designed by the university's architect, Louis Laybourne-Smith. It contained a special laboratory designed by Robertson, and was erected by the CSIR on the university's campus "upon land very generously made available for this purpose by the University" (BR.65). The CSIR Building, known today as The Brailsford Robertson Building, was opened by the Prime Minister, Stanley Bruce, on 22 October 1928.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.